RYTM News and Press, Rhythm Pharmaceuticals Inc. From 01/03/24

2024-01-03 07:00:00 ET Summary The biotech industry experienced a challenging year in 2023 due to a rising 10-year Treasury yield. In 2024, the 10-year yield should favorably support biotech stocks. Promising advancements in weight loss drugs, neuroscience, oncology, and gene ...

2023-12-25 06:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

-- More than 50 poster presentations highlighting new scientific developments to advance the care of people living with rare MC4R pathway diseases -- -- Approximately 150 healthcare professionals from 20 countries expected to attend -- BOSTON, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Rhy...

-- Phase 3 trial evaluating setmelanotide in pediatric patients ages 2-<6yo (N=12) over 52 weeks achieved primary endpoint -- -- Setmelanotide achieved 3.04 mean reduction in BMI-Z score and 18.4 percent mean reduction in BMI in patients ages 2-<6yo with obesity due to POMC/LEPR def...

2023-12-04 21:29:35 ET Summary Baker Brothers' 13F portfolio value increased marginally from $17.28B to $17.35B. The largest five stakes in the portfolio are Seagen, BeiGene, Incyte, ACADIA Pharma, and BioMarin Pharma, making up approximately 86% of the portfolio. Stake increa...

2023-12-01 12:50:00 ET More on Pfizer, Rhythm Pharma etc. Pfizer Inc. (PFE) 6th Annual Evercore ISI HealthCONx Conference (Transcript) Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips Rhythm Pharmaceuticals: Major Catalysts Due For Weight Loss Specia...

2023-11-21 02:58:46 ET Summary Rhythm Pharmaceuticals' stock has experienced significant volatility, soaring and plunging multiple times since its IPO in 2017. The company's lead drug, Imcivree, was approved for chronic weight management in patients with specific genetic deficienc...

2023-11-15 07:00:00 ET Summary Biotech stocks, long burdened by concerns over rising yields, are poised for improvement as the 10-year yield may have peaked, signaling a potential upswing in the industry's fortunes. The recent uptrend in the 10-year yield, peaking around 5% in Oct...

2023-11-07 14:52:08 ET Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2023 Earnings Conference Call November 07, 2023 08:00 AM ET Company Participants David Connolly - Executive Director, IR and Corporate Communications David Meeker - Chairman, President, and CEO Jennife...

2023-11-07 07:08:17 ET More on Rhythm Pharmaceuticals Rhythm Pharmaceuticals Q3 2023 Earnings Preview Rhythm’s obesity therapy granted EU backing for orphan designation Seeking Alpha’s Quant Rating on Rhythm Pharmaceuticals For further details s...